


#18

Approved for use through 10/31/2012. OMB 851-0031
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Sheet 1 of 6

Attorney Docket No: 875.032US1

RECEIVED
JUN 12 2003
TECH CENTER 1600/2001

US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
AS	US-5,604,090	02/18/1997	Alexander, Ian E., et al.	435	25	06/06/1994
DS	US-5,691,176	11/25/1997	Lebkowski, J. S., et al.	435	172.3	06/02/1995
AS	US-5,834,182	11/10/1998	Alexander, Ian E., et al.	435	5	02/25/1997
DS	US-6,083,702	07/04/2000	Mitchell, L. G., et al.	435	6	08/13/1998
DS	US-6,200,560	03/13/2001	Couto, L. B., et al.	424	93.2	12/22/1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
DS	WO-94/13788 ✓	12/04/1992	Coruzzi, Laura A., et al.	C12N	7/01	
DS	WO-95/07351 ✓	09/10/1993	Jarrell, Kevin A.	C12N	15/10	
DS	WO-97/22250 ✓	12/13/1996 06/1997	Mitchell, Lloyd G.	A01N	43/04	
DS	WO-98/09657 ✓	09/06/1999 03/1999	Wilson, James M., et al.	A61K	48/00	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DS		"(S)-(+)-Camptothecin; 4-Ethyl-4-hydroxy-1H-pyrano[3', 4': 6, 7] indolizino [1,2-b] quinoline-3, 14 (4H, 12H) dione", <u>Calbiochem</u> , Camptothecin, Camptotheca acuminata, (October 2, 2000), 1-2	
DS		"Adriamycin; 14-Hydroxydaunomycin, HCl", <u>Calbiochem</u> , Doxorubicin, Hydrochloride, Catalog Number 324380, (October 21, 1998), 1-2	
DS		"Aminoglycoside antibiotic. Inhibits myeloperoxidase-dependent oxidant cell injury", <u>Calbiochem</u> , Tobramycin, Free Base, Catalog Number 614005, (August 26, 1999), 1	
DS		"Cancer Research", <u>Contribution to Society</u> , http://www.bikaken.or.jp/mcrf/e/contribution.(December 4, 2000), 2 pages	
DS		"Carbobenzoxy-L-leucyl-L-leucinal", <u>Calbiochem</u> , MG-132, Catalog Number 474790, (October 15, 1999), 1-2	
DS		"Drugs for Selection of Genetic Markers Reagents for positive and negative selection of Genes involved in Nucleotide Metabolism", <u>Calbiochem</u> , (March 2002), 6 pages	
DS		"EPA; 20:5 w-3; 5,8, 11, 14, 17-Eicosapentaenoic Acid", <u>Calbiochem</u> , Eicosapentaenoic Acid, Catalog Number 324875, (December 7, 1998), 1-2	
DS		"Epoxomicin- a potent and selective proteasome inhibitor", <u>Affiniti Research Products Limited</u> , 2 pages	
DS		"LDP-341", <u>Millennium Pharmaceuticals</u> , http://www:biospace.com/ct/detail.cfm?ClinicalID=266404, 1 page	
DS		"Mevinolin; MK-803", <u>Calbiochem</u> , Lovastatin, Catalog Number 438185, (June 29, 2001), 1-2	

EXAMINER

Sullivan

DATE CONSIDERED

7/25/03

Substitute Disclosure Statement Form (PTO-1449)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language translation is attached